Pamela Cox Presents Webinar “Life Science Start-Up Board IP & Licensing Considerations” for Women In Bio (WIB)

May 29, 2020

Chair of Marshall, Gerstein & Borun LLP's IP Transactions Practice, Pamela Cox will conduct a webinar for Women In Bio (WIB) Chicago Chapter’s recently formed 3.8 Initiative. Pam will focus on what life science startup board members might want to consider regarding the startup’s intellectual property assets, freedom to operate, and licensing and partnering opportunities.

Women In Bio is a national non-profit organization of professionals committed to fostering and encouraging entrepreneurship and career development of women active in the life sciences industry. Women In Bio’s 3.8 Initiative seeks to increase diversity in the healthcare community in the Chicagoland area and create a forum by which women can safely discuss and address the challenges they face in leadership positions. Marshall Gerstein is proud to support Women In Bio’s mission to help women achieve the highest levels of leadership, influence, and decision-making.

A member of WIB, Pam Cox, is recognized as one of the country’s leading licensing authorities, particularly in life sciences. Her practice focuses on IP transactions, IP strategies, and dispute resolution for clients ranging from multinational corporations to non-profit institutions. Committed to advancing the profession, last year Pam co-founded the Women in Licensing Alliance (WILA), an organization dedicated to advancing the growth of women in leadership through education, mentoring, and networking opportunities. WILA is a part of the Licensing Executives Society International (LESI), for which she is Corporate Secretary of the Board and Vice President. She is also Corporate Secretary of the Board for the University Club of Chicago. Avid teacher, Pam is an Adjunct Professor at Northwestern University Pritzker School of Law and is an invited speaker around the world on intellectual property transactions and alternative dispute resolution.

Offsite Notice

By clicking “Proceed” below, you will be opening a new browser window and leaving our website.